Search

Lactic acid bacteria (LAB) are an important group of microorganisms in the food industry. LAB with health benefits are considered natural elements promoting consumer health. The study investigated the anti‐obesity effects of Lactobacillus plantarum CQPC01 (LP‐CQPC01) on high‐fat diet‐induced mice. Liver morphology, liver function indexes, lipid indexes, and inflammatory factors in the serum and liver were determined. Expressions of lipid metabolism‐related gene were also detected by qPCR. LP‐CQPC01 slowed the HFD‐induced increase in body weight, decreased the organ indexes, alleviated hepatic lipid accumulation, and inhibited the increased adipose cell volume. LP‐CQPC01 decreased lipid levels of serum and liver, and the contents of pro‐inflammatory factors, and increased the IL‐4 and IL‐10 contents. LP‐CQPC01 downregulated the expressions of the C/EBP‐α and PPARγ mRNA and upregulated CYP7A1, CPT1, LPL, CAT, SOD1, and SOD2 mRNA. Our results indicated that LP‐CQPC01 is a potential probiotic for preventing or alleviating high‐energy intake‐related lipid conditions. Practical applications: Obesity is a factor of a variety of cardiovascular diseases. Therefore, it is necessary to suppress the occurrence of fat accumulation in time. This study investigated the effect of LP‐CQPC01 on lipid regulation in mice fed a high‐fat diet (HFD) and clarified the mechanism of strain to alleviate obesity by enhancing the decomposition of cholesterol and detoxification of fat. LP‐CQPC01 reduced fat accumulation without oxidative damage, and was confirmed by the attenuated pathological changes of liver. This research can serve as a significant reference for future research, prevention, and treatment of high‐energy intake‐related lipid conditions, and the development of functional foods with anti‐obesity activity. [ABSTRACT FROM AUTHOR]

The protective effect of Lactobacillus plantarum YS3 (LP‐YS3) on ulcerative colitis (UC) was assessed using a mouse model of dextran sodium sulfate (DSS)‐induced colitis. Different concentrations of LP‐YS4 were administered to the experimental mice by daily gavage. Several inflammatory and biochemical indices, such as interleukin‐2 (IL‐2), interleukin‐10 (IL‐10), interleukin‐6 (IL‐6), interleukin‐1 beta (IL‐1β), tumor necrosis factor‐alpha (TNF‐α), glutathione (GSH), malondialdehyde (MDA), myeloperoxidase (MPO), and nitric oxide (NO), were examined in mouse serum and colon tissue. The mRNA and protein expression levels of c‐Kit, CXC chemokine receptor type 2 (CXCR2), interleukin‐8 (IL‐8), and stem cell factor (SCF) in mouse colon tissue were assessed using Western blot and quantitative polymerase chain reaction (qPCR) assays. The findings indicated that LP‐YS3 remarkably decreased the disease activity index (DAI) of UC mice (p <.05), inhibited colon length shortening induced by UC, and elevated the value of colon weight/length ratio. LP‐YS3 could also markedly reduce (p <.05) the activities of MDA, MPO, and NO; while an increase in the GSH content in the colonic tissue of UC mice. Moreover, LP‐YS3 remarkably increased (p <.05) the serum level of IL‐2 in UC mice, while reduced those of IL‐10, IL‐6, IL‐1β, TNF‐α cytokines. qPCR data revealed that LP‐YS3 could markedly upregulate the expression levels of c‐Kit and SCF, while downregulate those of CXCR2 and IL‐8 in the colonic tissue of UC mice (p <.05). LP‐YS3 exerted an outstanding protective effect on DSS‐induced colitis in C57BL/6J mice, especially at higher concentrations. Practical applications: Lactobacillus plantarum YS3 is a newly isolated and identified lactic acid bacteria. This study confirmed that L. plantarum YS3 can inhibit colitis and has good probiotic potential, which needs further development and utilization. [ABSTRACT FROM AUTHOR]

Probiotics are regard as safety approaches for preventing and treating some chronic diseases. This study investigated the regulating effect of Lactobacillus plantarum CQPC03 (LP‐CQPC03) on lipid metabolism in high‐fat diet (HFD)‐induced obesity in mice. The results showed that administration of LP‐CQPC03 at a concentration of 1.0 × 109 CFU/kg body weight inhibits HFD‐induced obesity and improves lipid metabolism in the liver and serum. LP‐CQPC03 intervention attenuated obesity‐induced hepatic tissue damage, led decreases in hepatic triglyceride (42.02 mmol/gprot), total cholesterol (3.85 mmol/gprot), and LDL‐C (1.03 mmol/gprot), and an increase in HDL‐C (1.07 mmol/gprot). The same tendencies were observed in serum of HFD‐fed mice. LP‐CQPC03 intervention led a decrease in serum levels of aspartic transaminase, alanine transaminase, and alkaline phosphatase. LP‐CQPC03 alleviated inflammation by increasing the level of interleukin (IL)‐4 and IL‐10, and decreasing the levels of pro‐inflammatory factors, including IL‐6, IL‐1β, tumor necrosis factor‐α, and interferon‐γ. LP‐CQPC03 also increased activities of SOD and GSH‐Px in liver significantly and dropped the hepatic malondialdehyde (MDA) level from 3.39 nmol/gprot to 1.90 nmol/gprot. RT‐qPCR results showed that the lipid metabolism‐improving effect of LP‐CQPC03 was performed by upregulating the expression of carnitine palmitoyltransferase 1, lipoprotein lipase, catalase, and superoxide dismutase 1. This study indicates that L. plantarum CQPC03 might be a potential probiotic that can help mitigate the adverse effects of excessive lipids on the liver, and prevent or alleviate high‐energy intake‐related obesity. Practical applications: Intaking high‐energy foods is a potential risk of lipid metabolic disorder. Therefore, it is necessary to seek an effective and safe approach for preventing the obesity‐related disease. This study found that LP‐CQPC03 limited the rate of increase in body weight of mice fed on HFD, maintained normal hepatic tissue morphology, and exhibited a strong regulating effect on lipid metabolism. And the threshold concentration of LP‐CQPC03 for the lipid‐lowering effect was 1.0 × 109 CFU/kg body weight. Therefore, LP‐CQPC03 is a potential probiotic for preventing or alleviating high‐energy intake‐related obesity. [ABSTRACT FROM AUTHOR]